Intellia Therapeutics (NASDAQ: NTLA) underwent analysis by 21 analysts in the last quarter, revealing a spectrum of ...
ERS Genomics Limited (‘ERS’), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company ...
ERS Genomics Limited ('ERS'), the CRISPR licensing company, and Dyadic Applied BioSolutions, a global biotechnology company producing precision-engineered ...
New study has discovered a groundbreaking technology that is showing remarkable success in significantly reducing bad ...
Scientists at the University of Glasgow have successfully used the first bioengineered bone marrow model to carry out vital ...
Technology opens the door to more accurate preclinical testing, which could enable the development of safer and more effective therapies.
In a world first, a bespoke gene-editing therapy benefitted one child. Now reseachers plan to launch a clinical trial of the approach.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback